Elevance Health
Stock Forecast, Prediction & Price Target
Elevance Health (ELV) stock Price Target by analysts
Elevance Health (ELV) stock Price Target by analysts
Average Price Target
$525.33
Potential upside: 68.71%
Elevance Health price prediction
What is Elevance Health stock analysts` prediction?
Elevance Health stock forecast: Based on 6 Wall Street analysts` predicted price targets for Elevance Health in the last 3 months, the avarage price target is $525.33, with a high forecast of $NaN. The average price target represents a 68.71% change from the last price of $311.38.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Elevance Health stock Price Target by analysts
Full breakdown of analysts given Elevance Health price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
David Windley Jefferies | 0% 0/3 | 11 months ago | $529 69.88% upside | $430.77 | StreetInsider | Previous targets (2) |
Whit Mayo Leerink Partners | 0% 0/1 | 11 months ago | $515 65.39% upside | $430.77 | StreetInsider | Previous targets (0) |
Ben Hendrix RBC Capital | 20% 1/5 | 11 months ago | $478 53.51% upside | $444.35 | StreetInsider | Previous targets (4) |
Sarah James Raymond James | 0% 0/1 | 11 months ago | $485 55.75% upside | $432.53 | Benzinga | Previous targets (0) |
David MacDonald Truist Financial | 0% 0/3 | 11 months ago | $520 66.99% upside | $444.35 | StreetInsider | Previous targets (2) |
Michael Ha Robert W. Baird | 0% 0/2 | 12 months ago | $625 100.71% upside | $483.87 | StreetInsider | Previous targets (1) |
Ben Hendrix RBC Capital | 20% 1/5 | about 1 year ago | $585 87.87% upside | $502.06 | TheFly | Previous targets (4) |
David MacDonald Truist Financial | 0% 0/3 | about 1 year ago | $620 99.11% upside | $535.54 | TheFly | Previous targets (2) |
Erin Wright Morgan Stanley | 0% 0/1 | over 1 year ago | $643 106.50% upside | $534.42 | TheFly | Previous targets (0) |
Michael Ha Robert W. Baird | 0% 0/2 | over 1 year ago | $649 108.42% upside | $505.52 | TheFly | Previous targets (1) |
Ben Hendrix RBC Capital | 20% 1/5 | over 1 year ago | $575 84.66% upside | $525.19 | StreetInsider | Previous targets (4) |
Stephen Baxter Wells Fargo | 0% 0/2 | over 1 year ago | $600 92.69% upside | $525.19 | StreetInsider | Previous targets (1) |
AJ Rice UBS | 0% 0/1 | over 1 year ago | $605 94.29% upside | $525.19 | StreetInsider | Previous targets (0) |
Andrew Mok Barclays | 0% 0/1 | over 1 year ago | $621 99.43% upside | $525.19 | TheFly | Previous targets (0) |
David Windley Jefferies | 0% 0/3 | over 1 year ago | $604 93.97% upside | $525.19 | StreetInsider | Previous targets (2) |
Unknown Mizuho Securities | N/A | almost 3 years ago | $575 84.66% upside | $521.88 | Benzinga | N/A |
Joseph France Loop Capital Markets | 0% 0/1 | over 3 years ago | $550 76.63% upside | $454.76 | TheFly | Previous targets (0) |
Stephen Baxter Wells Fargo | 0% 0/2 | over 3 years ago | $580 86.26% upside | $501.53 | Pulse 2.0 | Previous targets (1) |
Unknown BMO Capital | N/A | over 3 years ago | $625 100.71% upside | $495.61 | Benzinga | N/A |
Unknown Deutsche Bank | N/A | over 3 years ago | $574 84.34% upside | $510.41 | Benzinga | N/A |
Ben Hendrix RBC Capital | 20% 1/5 | over 3 years ago | $544 74.70% upside | $522.87 | StreetInsider | Previous targets (4) |
Jonathan Yong Credit Suisse | 0% 0/1 | over 3 years ago | $584 87.55% upside | $522.87 | StreetInsider | Previous targets (0) |
Unknown Leerink Partners | N/A | over 3 years ago | $555 78.23% upside | $529.84 | Benzinga | N/A |
Unknown Goldman Sachs | N/A | over 3 years ago | $605 94.29% upside | $529.84 | Benzinga | N/A |
Unknown Morgan Stanley | N/A | over 3 years ago | $607 94.93% upside | $528.45 | Benzinga | N/A |
Michael Newshel Evercore ISI | 100% 2/2 | over 3 years ago | $335 7.58% upside | $529.84 | TipRanks Contributor | Previous targets (1) |
Ann Hynes Mizuho Securities | 100% 1/1 | over 3 years ago | $510 63.78% upside | $529.84 | TipRanks Contributor | Previous targets (0) |
David Windley Jefferies | 0% 0/3 | over 3 years ago | $625 100.71% upside | $529.84 | TipRanks Contributor | Previous targets (2) |
David MacDonald Truist Financial | 0% 0/3 | over 3 years ago | $590 89.47% upside | $510.64 | Pulse 2.0 | Previous targets (2) |
Kevin Caliendo UBS | 100% 1/1 | over 3 years ago | $541 73.74% upside | $489.34 | Pulse 2.0 | Previous targets (0) |
Matthew Borsch BMO Capital | 100% 1/1 | over 3 years ago | $510 63.78% upside | $434.61 | StreetInsider | Previous targets (0) |
Lisa Gill J.P. Morgan | 100% 1/1 | over 3 years ago | $500 60.57% upside | $434.61 | TipRanks Contributor | Previous targets (0) |
Ben Hendrix RBC Capital | 20% 1/5 | over 3 years ago | $452 45.16% upside | $434.61 | TipRanks Contributor | Previous targets (4) |
Michael Newshel Evercore ISI | 100% 2/2 | over 3 years ago | $335 7.58% upside | $427.24 | TipRanks Contributor | Previous targets (1) |
Joseph France Seaport Global | 100% 1/1 | over 3 years ago | $480 54.15% upside | $427.24 | StreetInsider | Previous targets (0) |
Lance Wilkes Bernstein | 0% 0/1 | over 3 years ago | $574 84.34% upside | $452.46 | TheFly | Previous targets (0) |
Steve Baxter Wells Fargo | 100% 1/1 | over 3 years ago | $523 67.96% upside | $438.22 | TipRanks Contributor | Previous targets (0) |
Nathan Rich Goldman Sachs | 100% 1/1 | almost 4 years ago | $517 66.03% upside | $432.72 | TheFly | Previous targets (0) |
Justin Lake Wolfe Research | 100% 1/1 | almost 4 years ago | $433 39.05% upside | $403.96 | StreetInsider | Previous targets (0) |
Steven Valiquette Barclays | 100% 1/1 | almost 4 years ago | $485 55.75% upside | $428 | TheFly | Previous targets (0) |
Kevin Fischbeck Bank of America Securities | 100% 1/1 | almost 4 years ago | $465 49.33% upside | $428 | StreetInsider | Previous targets (0) |
A.J. Rice Credit Suisse | 100% 1/1 | almost 4 years ago | $486 56.07% upside | $428 | StreetInsider | Previous targets (0) |
Steven Halper Cantor Fitzgerald | 100% 1/1 | almost 4 years ago | $470 50.94% upside | $421.68 | StreetInsider | Previous targets (0) |
Elevance Health Financial Estimates
Elevance Health Revenue Estimates
Elevance Health EBITDA Estimates
Elevance Health Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | |
Revenue
% change YoY
| $138.63B N/A | $156.59B 12.95% | $171.34B 9.41% | Avg: $182.32B Low: $178.30B High: $187.66B avg. 6.41% | Avg: $194.23B Low: $191.18B High: $198.39B avg. 6.53% | Avg: $228.34B Low: $224.75B High: $233.23B avg. 17.56% | |
Net Income
% change YoY
| $6.15B N/A | $5.89B -4.28% | $5.98B 1.57% | Avg: $9.06B Low: $8.83B High: $9.57B avg. 51.49% | Avg: $9.91B Low: $10.13B High: $10.82B avg. 9.29% | Avg: $12.74B Low: $12.48B High: $13.10B avg. 28.60% | |
EBITDA
% change YoY
| $9.22B N/A | $9.44B 2.35% | $10.49B 11.07% | Avg: $9.69B Low: $9.48B High: $9.98B avg. -7.53% | Avg: $10.33B Low: $10.17B High: $10.55B avg. 6.53% | Avg: $12.14B Low: $11.95B High: $12.40B avg. 17.56% | |
EPS
% change YoY
| $25.04 N/A | $24.56 -1.91% | $25.69 4.60% | Avg: $39.49 Low: $37.2 High: $40.35 avg. 53.72% | Avg: $44.53 Low: $42.71 High: $45.61 avg. 12.75% | Avg: $53.7 Low: $52.6 High: $55.2 avg. 20.59% | |
Operating Expenses
% change YoY
| $15.91B N/A | $17.68B 11.13% | $36.23B 104.88% | Avg: $25.95B Low: $25.38B High: $26.71B avg. -28.36% | Avg: $27.65B Low: $27.22B High: $28.24B avg. 6.53% | Avg: $32.51B Low: $32.00B High: $33.20B avg. 17.56% | |
FAQ
What is Elevance Health stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 29.79% in 2025-2027.
We have gathered data from 15 analysts. Their low estimate is 8.83B, average is 9.06B and high is 9.57B.
What is Elevance Health stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 10.16% in 2025-2027.
We have gathered data from 16 analysts. Their low revenue estimate is $178.30B, average is $182.32B and high is $187.66B.
What is Elevance Health stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 29.02% in 2025-2027.
We have gathered data from 15 analysts. Their low earnings per share estimate is $37.2, average is $39.49 and high is $40.35.
What is the best performing analyst?
In the last twelve months 6 analysts have been covering Elevance Health stock. The most successful analyst is David Windley.